Novo Nordisk initiates 2026 share repurchase programme

Core Viewpoint - Novo Nordisk A/S is initiating a share repurchase program for 2026, with a total amount of up to DKK 15 billion, starting on 4 February 2026, and a specific program of up to DKK 3.8 billion running from 4 February 2026 to 4 May 2026 [1]. Group 1: Share Repurchase Program - The share repurchase program aims to reduce the company's share capital and fulfill obligations from share-based incentive programs, allowing for the purchase of a maximum of 400,000,000 B shares of DKK 0.10 during the trading period [1]. - An authorization for the company to repurchase its own shares was granted at the Annual General Meeting on 27 March 2025, and continuation of the program beyond 26 March 2026 is contingent upon receiving further authorization at the Annual General Meeting in 2026 [2]. Group 2: Regulatory Compliance - The share repurchase program will be conducted in accordance with Article 5 of Regulation No 596/2014 and the Commission Delegated Regulation (EU) 2016/1052, adhering to the "Safe Harbour Rules" [3]. Group 3: Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923, headquartered in Denmark, and focuses on combating serious chronic diseases, particularly diabetes [4]. - The company employs approximately 68,800 people across 80 countries and markets its products in around 170 countries, with its B shares listed on Nasdaq Copenhagen and ADRs on the New York Stock Exchange [4].